DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers

Clinical Trials, Metastatic Castration Resistant Prostate Cancer (MCRPC)

— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives

NCT Number: NCT04388852
Phase: Phase 1
Trial Summary: This phase Ib trial studies the side effects and best dose of DS3201 when given together with and ipilimumab for the treatment of patients with prostate, urothelial, or renal cell – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): M.D. Anderson Cancer Center|National Cancer Institute (NCI)
Acronym:

Pin It on Pinterest